{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"5.5","value":"1.85"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"5.7","value":"1.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Low Risk"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"2.5","value":"1.16"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"3.2","value":"1.08"},{"groupId":"OG002","lowerLimit":"6.0","upperLimit":"12.2","value":"9.1"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"2.5","value":"0.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"95"},{"groupId":"OG002","value":"333"},{"groupId":"OG003","value":"118"}],"units":"Participants"}],"title":"Intermediate Risk"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"8.6","value":"3.64"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"12.8","value":"6.52"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"8.2","value":"3.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"63"},{"groupId":"OG003","value":"58"}],"units":"Participants"}],"title":"High Risk"}],"denoms":[{"counts":[{"groupId":"OG000","value":"372"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"451"},{"groupId":"OG003","value":"176"}],"units":"Participants"}],"description":"Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation.","dispersionType":"95% Confidence Interval","groups":[{"description":"No Nelarabine, Capizzi Methotrexate","id":"OG000","title":"ARM I (Combination Chemotherapy)"},{"description":"Nelarabine, Capizzi Methotrexate","id":"OG001","title":"ARM II (Combination Chemotherapy)"},{"description":"No Nelarabine, High-Dose Methotrexate","id":"OG002","title":"ARM III (Combination Chemotherapy)"},{"description":"Nelarabine, High-Dose Methotrexate","id":"OG003","title":"ARM IV (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Includes only low risk, intermediate risk and high risk T-cell Acute Lymphoblastic Leukemia (T-ALL) subjects. There were no low risk participants on Arm II and Arm IV. Patients with CNS3, and Induction Failures are excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"4 years from randomization at the end of induction","title":"Cumulative Incidence of CNS Relapse for T-ALL by Risk Group","type":"SECONDARY","unitOfMeasure":"percent probability"}